Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome trial 16 (AML16)

National Cancer Research Institute Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome Trial 16

Entry to the AML16 trial closed to all new patients on the 31st November 2011.

Please be advised that the 2v3 (consolidation) randomisation in the AML16 trial is due to close to recruitment at midnight, 28th September 2012.

This will effectively close all randomisations available for the AML16 trial. Survival status of patients will still be followed up annually – the relevant forms will be sent out by HCTU at the start of 2013.

The trial team would like to take this opportunity to thank all participating centres for your outstanding contribution in recruiting patients to this trial.

Further Information

For more information about the trial, or a copy of the current approved protocol please contact Angela Grech ( or Ian Thomas ( on 02921 847909.

Please see the below link for the data entry ECRF for AML16:

A summary of previous AML16 amendments can be accessed by clicking on the link below:

Overall AML16 Amendment Summary

For an update on all AML trials, please see the latest HCTU newsletter.